Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BMS-986205 Clear all
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 2, 2026, 4:37 AM EDT
Withdrawn Phase 3 Interventional

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
BMS-986205, Nivolumab, Chemotherapy
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

NCT03312426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

NCT03362411
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

NCT03329846
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
BMS-986205, Nivolumab, Placebo
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

NCT03346837
View directory record Official record
Conditions
Malignancies Multiple
Interventions
BMS-986205, Itraconazole, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

NCT03936374
View directory record Official record
Conditions
Healthy
Interventions
BMS-986205, omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

NCT03695250
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
IDO1 Inhibitor BMS-986205, Nivolumab
Drug · Biological
Lead sponsor
Edward Kim
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

NCT02996110
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, BMS-986205, BMS-813160
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
New Haven, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 2, 2026, 4:37 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

NCT03854032
View directory record Official record
Conditions
Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
Interventions
Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT04047706
View directory record Official record
Conditions
Glioblastoma
Interventions
IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide, IDO1 Inhibitor BMS-986205 50 mg, IDO1 Inhibitor BMS-986205 100 mg
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

NCT02750514
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 2, 2026, 4:37 AM EDT
Withdrawn Phase 3 Interventional

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

NCT03386838
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, BMS-986205, Cetuximab, Cisplatin, Carboplatin, Fluorouracil
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 2, 2026, 4:37 AM EDT
Active, not recruiting Phase 2 Interventional

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

NCT04106414
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
Interventions
Nivolumab, BMS- 986205
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Metabolism Study in Healthy Male Participants

NCT03247283
View directory record Official record
Conditions
Cancer
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

NCT02935634
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

NCT03459222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Nivolumab, BCG, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
25
States / cities
Los Angeles, California • Riverside, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 2, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

NCT03661320
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 4:37 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Nivolumab, BMS-986205, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

NCT03378310
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986205 reference tablet, BMS-986205 tablet with free base
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

NCT02658890
View directory record Official record
Conditions
Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
Interventions
BMS-986205, Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 100 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 2, 2026, 4:37 AM EDT